Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Scientists comment on Robert F. Kennedy Jr cancelling funding for mRNA vaccines. Prof Adam Finn, Professor of Paediatrics, University of Bristol, said: ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...